Carl Danzig is an Ophthalmology physician. OpenAlex indexes 38 publications with 1,845 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
28901 Trails Edge Blvd Ste 202
Bonita Springs, FL 341347588
Telephone
239-544-3122Provider last certified this registry record 22 Dec 2025.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year202561 payments$91,955openpaymentsdata.cms.gov ↗
- Ocular Therapeutix, Inc.Program year202546 payments$36,075openpaymentsdata.cms.gov ↗
- Genentech USA, Inc.Program year202511 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
95.5%Antineovascularisation agents77.7%Faricimab-svoa93%Vabysmo7%Part D + Part B≥92 patientsComplement Inhibitor8.8%Avacincaptad pegol87%Izervay13%Part D + Part B≥16 patients+ 9 more classes in this area
Cancer & immunology
3.3%Vascular Endothelial Growth Factor Inhibitor3.1%Eylea63%Eylea Hd37%Part D≥49 patientsCalcineurin inhibitor0.2%Restasis100%Part D<11 patientsMusculoskeletal
1%Cyclooxygenase Inhibitor1%Ketorolac Tromethamine100%Part D≥31 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Zusammenhang zwischen früher Auflösung von Makulaleckagen, Visusgewinn und verlängerten Behandlungsintervallen bei Patienten mit RVV: Eine Post-hoc-Analyse von BALATON/COMINO
German Medical Science (German Research Foundation)
2026 - Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion
Ophthalmology Retina
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”